Single-cell RNA sequencing identifies an inflammatory subpopulation of mesenchymal stromal cells in patients with multiple myeloma.
References
Dhodapkar, M. V. Blood 128, 2599–2606 (2016).
Das, R. et al. Nat. Med. 22, 1351–1357 (2016).
Zavidij, O. et al. Nat. Cancer 1, 493–506 (2020).
Reagan, M. R. & Ghobrial, I. M. Clin. Cancer Res. 18, 342–349 (2011).
de Jong, M. E. M. et al. Nat. Immunol. https://doi.org/10.1038/s41590-021-00931-3 (2021).
Baryawno, N. et al. Cell 177, 1915–1932.e16 (2019).
Lemaitre, L. et al. Int. J. Mol. Sci. 21, 3854 (2020).
Vande Broek, I. et al. Br. J. Cancer 88, 855–862 (2003).
Qian, H., Le Blanc, K. & Sigvardsson, M. J. Biol. Chem. 287, 25795–25807 (2012).
Munshi, N. C. et al. Blood Adv. 4, 5988–5999 (2020).
Alameda, D. et al. Haematologica 105, e470–e473 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.S.P. has no competing interests to disclose. N.J.H. is a consultant for Constellation Pharmaceuticals. I.M.G has a consulting and advisory role with Celgene, Takeda, Bristol-Myers Squibb, Genentech, Janssen Pharmaceuticals and Amgen and has received research funding/honoraria from Celgene, Takeda, Bristol-Myers Squibb, Janssen Pharmaceuticals and Amgen. G.G. receives research funds from IBM and Pharmacyclics and is an inventor on patent applications related to MuTect, ABSOLUTE, MutSig, MSMuTect, MSMutSig, MSIdetect, POLYSOLVER and TensorQTL. G.G. is a founder, consultant and holds privately held equity in Scorpion Therapeutics.
Rights and permissions
About this article
Cite this article
Sklavenitis-Pistofidis, R., Haradhvala, N.J., Getz, G. et al. Inflammatory stromal cells in the myeloma microenvironment. Nat Immunol 22, 677–678 (2021). https://doi.org/10.1038/s41590-021-00947-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-021-00947-9
- Springer Nature America, Inc.